December 24
|
Ondine Announces Toronto Stock Exchange Listing
|
December 13
|
Ondine Biopharma and Henry Schein enter into strategic distribution agreement
|
December 8
|
Ondine Biopharma Announce Changes to the Board of Directors
|
November 15
|
Ondine Biopharma Announces First Quarter 2005 Results
|
October 7
|
Stock Options
|
September 30
|
Ondine Biopharma Corporation Announces Year End Fiscal 2004 Financial Results
|
September 1
|
Ondine Appoints New President and CEO
|
August 9
|
Ondine Commences Trading on the AIM Exchange
|
August 6
|
Ondine Biopharma Announces Third Quarter Fiscal 2004 Financial Results
|
July 30
|
Ondine Expands Operating Team
|
July 26
|
Ondine publishes advance notice of AIM listing
|
July 21
|
Ondine signs Option Agreement for technology to treat MRSA, using PhotoDynamic Disinfection Technology
|
July 14
|
Ondine Biopharma increases Private Placement
|
July 7
|
Ondine Biopharma Retains The Equicom Group
|
June 30
|
Ondine Biopharma completes Cdn $16.9 million Private Placement
|
June 14
|
Private Placement of up to $20 million
|
June 2
|
Report pursuant to Section 111 of the Securities Act
|
May 19
|
Stock Options
|
May 13
|
Ondine closes $1 million brokered private placement
|
May 6
|
Letter-of-Intent signed for North American Distribution
|
April 29
|
Ondine Biopharma Corporation Announces New Director Appointments
|
April 26
|
FDA Agrees to Combination Product Jurisdiction
|
April 21
|
NEWS RELEASE - PROPERTY ASSET AGREEMENT[MARKET NEWS]
|
April 8
|
NOTICE TO SHAREHOLDERS - LETTER OF TRANSMITTAL
|
April 2
|
Ondine to raise $1 million in brokered private placement
|
April 1
|
NEWS RELEASE - GRADUATION TO TSX VENTURE[MARKET NEWS]
|
April 1
|
NEWS RELEASE - RESUME TRADING REVERSE TAKEOVER COMPLETED PROP[MARKET NEWS]
|
April 1
|
Ondine Biopharma Corporation announces completion of acquisition of assets and financing |
